Traditional Medicine for Memory Enhancement

Super Memory Formula

Dementia Diet

Get Instant Access

Melanie-Jayne R. Howes and Peter J. Houghton

Abstract In traditional practices of medicine, numerous plants have been used to alleviate memory impairment both in healthy individuals and those with disease states which are now recognised as specific cognitive disorders such as Alzheimer's disease (AD). An ethnopharmacological approach has provided leads to identify plants and their compounds that may have potential to modulate cognitive abilities by different modes of action. A variety of therapeutic targets have been identified as relevant in the treatment of cognitive disorders, including modulation of the cholinergic system, which may be achieved by the inhibition of acetyl-cholinesterase (AChE), and neuroprotection against glutamate-induced overstimulation of N-methyl-d-aspartate (NMDA) receptors, by the use of NMDA receptor modulators. Other activities considered to be relevant in the alleviation of cognitive impairment include anti-inflammatory, antioxidant and estrogenic activities. Two of the currently licensed drugs used to treat cognitive symptoms in AD, galantamine and rivastigmine, were derived from plant sources and have been characterised as inhibitors of AChE. However, some plant extracts which occur as a complex mixture of components, such as Ginkgo biloba L. extract, have demonstrated relevant biological activities in relation to cognitive function, but the compounds responsible for the observed effects or the mechanisms of action have not been well characterised. Amongst the many plants reputed to enhance cognitive function in a variety of traditional medicines including Ayurvedic, Chinese, European, African and South American medicines, relatively few have been extensively studied to determine any pharmacological basis for their historical uses. Some of those plants that have generated particular interest in understanding and establishing their potential for alleviating cognitive impairment are discussed.

Keywords Acetylcholinesterase inhibitors • Alzheimer's disease • Anti-inflammatory • Antioxidant • Estrogenic • Memory • Traditional medicine

Royal Botanic Gardens, Jodrell Laboratory, Kew, Richmond, Surrey, TW9 3AB, UK e-mail: [email protected]

K.G. Ramawat (ed.), Herbal Drugs: Ethnomedicine to Modern Medicine, DOI 10.1007/978-3-540-79116-4_15, © Springer-Verlag Berlin Heidelberg 2009

Abbreviations

ACh

Acetylcholine

AChE

Acetylcholinesterase

AD

Alzheimer's disease

AMPA

Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid

APP

Amyloid precursor protein

Anti-ChE

Anti-cholinesterase

BACE

ß-Secretase

BChE

Butyrylcholinesterase

ChAT

Choline acetyltransferase

ChE

Cholinesterase

CNS

Central nervous system

COX

Cyclo-oxygenase

DMHA

Dimethylhuperzine A

ERT

Estrogen-replacement therapy

GABA

Y-Aminobutyric acid

5-HT

5-Hydroxytryptamine

IL-1

Interleukin-1

KUT

Kami-utan-to

LOX

Lipoxygenase

ltb4

Leukotriene B4

mRNA

Messenger ribonucleic acid

NF-kB

Nuclear transcription factor kB

NGF

Nerve growth factor

NMDA

N-methyl-d-aspartate

NO

Nitric oxide

NSAID

Non-steroidal anti-inflammatory drug

PAF

Platelet-activating factor

PG

Prostaglandin

PUFA

Polyunsaturated fatty acid

TCM

Traditional Chinese medicine

TNF

Tumour necrosis factor

VIP

Vasoactive intestinal peptide

15.1 Introduction 15.1.1 Cognitive Disorders

Loss of memory may occur in healthy people, where it is often associated with the ageing process, or it may also occur in specific disease states in which cognitive function is impaired. Cognitive dysfunction can be a feature of a variety of disorders, including schizophrenia [1], multiple sclerosis [2], and the many pathologies associated with dementia. Dementia, which involves a deterioration of cognition, may present in patients with central nervous system (CNS) infections, Huntington's disease, Parkinson's disease, Lewy body disease, Pick's disease, vascular disease and Alzheimer's disease (AD) [3,4]. AD is reported to be the most common type of dementia [4] and is estimated to account for between 50% and 60% of dementia cases in persons over 65 years of age [5]. There is a need for effective therapies that target loss of memory both in healthy individuals and those with specific disorders that involve cognitive impairment. At present there is a lack of therapeutic substances that can alleviate memory loss in both cases. There are many challenges involved in developing effective therapies for treating or preventing general memory loss associated with ageing and for treating or preventing the memory impairment which is a feature of the different pathologies associated with the variety of cognitive disorders such as dementia, although there may be some common therapeutic targets which may be investigated to alleviate cognitive impairment in different disease states and in general memory loss. The common symptoms of neurodegenerative diseases, such as loss of memory, have been recognised as a feature of increasing age for a long time, and it is these symptoms, rather than the specific disease states which are diagnosed in modern medicine, which have been acknowledged in many traditional practices of medicine.

15.1.2 Alzheimer's Disease

AD is a progressive, neurodegenerative disease that primarily affects the elderly population and it is a major public health concern. The etiology of AD is still not fully understood. The main symptoms associated with AD involve cognitive dysfunction, which primarily involves loss of memory and recognition skills [4, 6, 7]. Several other features present in the later stages of the disease, including language deficits, depression, agitation, mood disturbances and psychosis [8, 10]. Although the pathology of AD has not been fully elucidated, senile plaque and neurofibrillary tangle formation, and associated oxidative and inflammatory processes and neurotransmitter disturbances, occur in the CNS. In particular, a consistent neuropatho-logical feature associated with memory loss is a deficit of acetylcholine (ACh) (1), a neurotransmitter which is associated with cognitive function, and a cholinergic deficit has been correlated with the severity of AD [11-14].

15.1.3 Cholinergic Function

The presynaptic synthesis of ACh (1) from choline and acetyl coenzyme A in neurons is catalysed by the enzyme choline acetyltransferase (ChAT) [15]. Once synthesised, ACh is stored in synaptic vesicles and is released upon neuronal stimulation into the synaptic cleft [15]. ACh may then stimulate postsynaptic receptors (or presynaptic receptors to regulate ACh release) before being hydrolysed at the ester bond in the ACh molecule to yield choline and acetate, under the action of the enzyme acetylcholinesterase (AChE). Thus, ACh has a short half-life, and attempts to prolong its action have been investigated as a therapeutic target to restore cholinergic function in some cognitive disorders such as dementia.

AChE consists of a complex protein of the a/p hydrolase-fold type having an overall ellipsoid shape containing a deep gorge about 20 A in depth. At the bottom of this gorge are four main subsites known as the 'esteratic site', the 'oxyanion hole', the 'anionic subsite' and the 'acyl pocket', and it is in this region where ACh hydrolysis appears to occur, although the initial binding of ACh is thought to occur at an outer region known as the 'peripheral site' [16]. In addition to its role in hydrolysing ACh, AChE has also been associated with other functions including a role as an adhesion protein, a bone matrix protein, in neurite growth and in the production of amyloid fibrils, which are characteristically found in the brain tissue of AD patients [17], although the clinical relevance of these actions has yet to be explored more thoroughly. Another type of cholinesterase (ChE) is butyryl-cholinesterase (BChE), which is found mainly in serum and glia, unlike AChE, which is mainly distributed in neurons and erythrocytes in vertebrates [18]. The physiological role of BChE is unclear, with no endogenous natural substrate having been identified. BChE is known to hydrolyse toxic esters such as cocaine, and it is considered to have a detoxifying action [18].

15.1.4 Symptoms Related to Memory Disorders in Traditional Practices of Medicine

Many disease states now known and characterised by diagnostic tests in modern orthodox 'Western' medicine, including cognitive disorders such as AD, were not recognised in the past as such in some more traditional practices of medicine, or may be described differently in other cultures. Consultation with traditional practitioners and healers or referral to historical literature is an unlikely approach to yield relevant information if modern medical terms are used. A more productive approach would involve searching for information according to the treatment of characteristic symptoms of a particular disease. AD is characterised by a loss of short-term and eventually long-term memory as a feature of general cognitive decline. In the later stages of the disease, language deficits, depression and agitation can occur. Therefore, investigations into traditional uses should be focused on those substances which have a reputation for improving memory or cause a general stimulation of learning processes or intellect, in whichever way it is viewed in a particular cultural context.

As well as those materials used for medicinal purposes, obtaining knowledge on the types and uses of poisonous substances may also provide some indication of their physiological effects. For example, a substance that produces symptoms of sweating, flushing of the skin and intestinal contractions may indicate that it contains compounds which stimulate cholinergic activity, perhaps by inhibiting AChE and thus ACh (1) hydrolysis. Compounds that may produce these effects could be of interest for study as potential cognitive enhancers.

It must also be emphasised that understanding the etiology of a disease in Western medicine may not be the same as that in other traditions. The approaches to treatment will reflect the symptoms which manifest and the recognised causes. Many African cultures include spiritual factors in the cause of disease, whilst Ayurvedic and Chinese medicine view the correction of imbalance as an aspect of the appropriate treatment. The interpretation of medical conditions described according to these traditional practices compared to the orthodox medical approach may present problems. Consequently, knowledge of the underlying pathologies which could be associated with the described and observed symptoms may be necessary to help characterise disease states.

Was this article helpful?

0 0
The Polarity Path

The Polarity Path

The Effects Polarity Has on Career and Health. Get All The Support And Guidance You Need To Be A Success At Understanding Polarity. This Book Is One Of The Most Valuable Resources In The World When It Comes To The Effects Polarity Has on Career and Health.

Get My Free Ebook


Post a comment